TYRA-430
- Generic Name
- TYRA-430
Overview
No overview information available.
Background
No background information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
TYRA-430: A Novel FGFR4/3-Biased Inhibitor for FGF/FGFR Pathway-Aberrant Cancers
1. Introduction to TYRA-430 and the FGF/FGFR Pathway in Cancer
1.1. Overview of TYRA-430
TYRA-430 is an investigational, orally administered, reversible, small-molecule inhibitor with a biased specificity for Fibroblast Growth Factor Receptor 4 (FGFR4) and Fibroblast Growth Factor Receptor 3 (FGFR3).[1] Developed by Tyra Biosciences, Inc., TYRA-430 is engineered as a next-generation precision medicine aimed at addressing cancers driven by aberrations in the FGF/FGFR signaling pathway, particularly advanced hepatocellular carcinoma (HCC) and other solid tumors.[4] Its development leverages the company's proprietary SNÅP (Structure-based NÅnobodies and Panel) platform, which facilitates rapid and precise drug design to overcome challenges such as acquired drug resistance.[1] The key characteristics of TYRA-430 are summarized in Table 1.
Table 1: TYRA-430 - Key Drug Characteristics
| Characteristic | Description | Source(s) |
|---|---|---|
| Drug Name (Synonyms) | TYRA-430 | General |
| Developer | Tyra Biosciences, Inc. | 4 |
| Drug Type | Small molecule, oral, reversible, FGFR4/3-biased inhibitor | 1 |
| Primary Targets | Fibroblast Growth Factor Receptor 4 (FGFR4), Fibroblast Growth Factor Receptor 3 (FGFR3) | 2 |
| Key Mechanism of Action | Inhibition of FGFR4 and FGFR3 kinase activity, particularly in the context of FGF19-driven signaling | 2 |
| Therapeutic Areas | Oncology (Neoplasms), Digestive System Disorders (specifically HCC) | 5 |
| Lead Indications | Advanced Hepatocellular Carcinoma (HCC) with FGF19 overexpression or other activating FGF/FGFR pathway aberrations; other advanced solid tumors with similar activating FGF/FGFR pathway aberrations | 1 |
1.2. The FGF/FGFR Signaling Pathway in Oncology
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.